CD274 and prostate cancer: They also observed that circulating PD-L1/2+ DCs significantly increased in mice bearing Enzalutamide resistant (ENZR) tumors compared to castration resistant prostate cancer, and ENZR tumors expressed significantly increasing levels of tumor-intrinsic PD-L1.